14th Annual report: Top 10 pipelines
Caution flags on spending are likely to lower this year as the race to revive pipelines intensifies. R&D Directions’ 14th annual report profiles the pharmaceutical industry’s 10 best therapeutic pipelines as chosen by our editors.
By Michael D. Christel

Site selection for clinical trials
The global recession is challenging CROs and sponsors to be extra diligent in choosing sites for clinical trials.
By Lyle Fitzsimmons

Editor's Page
Whether it’s product pipelines, or conference travel arrangements, expect to see a lot of waiting around in 2010
By Christiane Truelove

R&D Business
Celgene’s acquisition of Gloucester Pharmaceuticals Inc. strengthens company’s foothold in lymphoma.
By Colette Pilkus

Drugs in Development
Novartis and Incyte Corp. strike potential $1 billion hematology-oncology licensing deal.
By Colette Pilkus

Filed for Approval
Johnson & Johnson submits application for tapentadol extended release tablets for the management of chronic pain.
By Colette Pilkus
 

NIBR touts promising drugs, lab of future
Executives at the Novartis Institutes for BioMedical Research discuss the promise of targeting signaling pathway imbalances in treating a number of diseases.
By Christiane Truelove

Retiring Lilly R&D leader Steven Paul reflects on career
R&D Directions Managing Editor Michael Christel spoke with Steven Paul, M.D., executive VP, science and technology, and president, Lilly Research Laboratories. Dr. Paul is retiring from Lilly on Feb. 28 after almost 17 years with the company.
By Michael D. Christel

Secondary uses of electronic health records data in life sciences
Terri Cooper, principal and national Leader, Life Sciences R&D Practice, Deloitte Consulting, explores the value of integrating electronic health records data in drug development.
By Terri Cooper, Ph.D., national leader, and Glenn Carroll, manager, Life Sciences R&D Practice, Deloitte Consulting LLP

Q&A: Daniel Vasella
R&D Directions spoke with Daniel Vasella, M.D., chairman and CEO of Novartis, about the Swiss drugmaker’s unique approach to medical innovation, as well as key issues affecting the pharmaceutical industry.
By Michael D. Christel

Roche, Genentech preserve innovative cultures
R&D Directions spoke with executives at Roche and Genentech for their perspective on the combined organization’s new R&D model, which was established after the merger of the longtime partners last year.
By Michael D. Christel

Q&A: J&J and neuroscience
Husseini Manji, M.D., global therapeutic head, neuroscience, Johnson & Johnson Pharmaceutical Research & Development, answered questions from R&D Directions about J&J’s research efforts in central nervous system disorders, an area bolstered by its acquisition of Elan Corp.’s stake in the Alzhemier’s Immunotherapy Program.
By Michael D. Christel